Gene · 970
Papers4,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,041 to 1,060 of 4,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma. | Front Immunol | 2022 | 36505457 | PubTator, text mining | PubMed |
| Enrichment of T-cell proliferation and memory gene signatures of CD79A/CD40 costimulatory domain potentiates CD19CAR-T cell functions. | Front Immunol | 2022 | 36505428 | PubTator, text mining | PubMed |
| Lactate regulators contribute to tumor microenvironment and predict prognosis in lung adenocarcinoma. | Front Immunol | 2022 | 36505423 | PubTator, text mining | PubMed |
| Recent Update on the Anti-Inflammatory Activities of Propolis. | Molecules | 2022 | 36500579 | PubTator, text mining | PubMed |
| CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells. | Molecules | 2022 | 36500549 | PubTator, text mining | PubMed |
Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification. | Cancers (Basel) | 2022 | 36497332 | PubTator, text mining | PubMed |
| An Inflammatory Response-Related Gene Signature Can Predict the Prognosis and Impact the Immune Status of Lung Adenocarcinoma. | Cancers (Basel) | 2022 | 36497225 | PubTator, text mining | PubMed |
| The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma. | J Oncol | 2022 | 36483984 | PubTator, text mining | PubMed |
| Toll-like receptor-targeted anti-tumor therapies: Advances and challenges. | Front Immunol | 2022 | 36479129 | PubTator, text mining | PubMed |
| Human gut microbiota-reactive DP8α regulatory T cells, signature and related emerging functions. | Front Immunol | 2022 | 36479125 | PubTator, text mining | PubMed |
| Development of therapeutic vaccines for the treatment of diseases. | Mol Biomed | 2022 | 36477638 | PubTator, text mining | PubMed |
| N7-methylguanosine methylation-related regulator genes as biological markers in predicting prognosis for melanoma. | Sci Rep | 2022 | 36473947 | PubTator, text mining | PubMed |
| The dual role of CD70 in B-cell lymphomagenesis. | Clin Transl Med | 2022 | 36471481 | PubTator, text mining | PubMed |
| MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors. | J Oncol | 2022 | 36467498 | PubTator, text mining | PubMed |
| Rapid identification of CMV-specific TCRs via reverse TCR cloning system based on bulk TCR repertoire data. | Front Immunol | 2022 | 36466875 | PubTator, text mining | PubMed |
| Novel T-cell signature based on cell pair algorithm predicts survival and immunotherapy response for patients with bladder urothelial carcinoma. | Front Immunol | 2022 | 36466869 | PubTator, text mining | PubMed |
| Novel cellular senescence-related risk model identified as the prognostic biomarkers for lung squamous cell carcinoma. | Front Oncol | 2022 | 36465363 | PubTator, text mining | PubMed |
| Constrast-enhanced computed tomography radiomics predicts CD27 expression and clinical prognosis in head and neck squamous cell carcinoma. | Front Immunol | 2022 | 36458007 | PubTator, text mining | PubMed |
| Constructing a Tregs-associated signature to predict the prognosis of colorectal cancer patients: A STROBE-compliant retrospective study. | Medicine (Baltimore) | 2022 | 36451426 | PubTator, text mining | PubMed |
| Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. | EBioMedicine | 2022 | 36442320 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/970/papers?page=53